Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saravolatz Louis, Gandhi Tejal N, Vaughn Valerie M, Ratz David, Horowitz Jennifer K, Gupta Ashwin, McLaughlin Elizabeth, Czilok Tawny, Weinmann Allison, Paje David, Malani Anurag N, Burdick Stephanie, Osterholzer Danielle, Flanders Scott A, Petty Lindsay A
Аннотация
BACKGROUND: Immunocompromised patients are often excluded from pneumonia trials, guidelines, and stewardship interventions. The objective of this study was to evaluate whether empiric broad-spectrum antibiotic (BSA) treatment impacts mortality and other clinical outcomes in moderately immunocompromised patients without risk factors for multidrug-resistant organisms (MDROs) hospitalized with community-acquired pneumonia.
METHODS: This was a target trial emulation including moderately immunocompromised (asplenia, hematologic malignancies, solid organ malignancy receiving chemotherapy, kidney transplant >1 year prior, congenital/acquired immunodeficiency, and receiving immunosuppressive medications) patients with pneumonia without risk factors for MDROs at 69 hospitals in the Michigan Hospital Medicine Safety Consortium. This study compared the receipt of empiric BSAs against antibiotics targeting typical respiratory pathogens on hospital day 1 or 2. The primary outcome was mortality. Secondary outcomes included length of stay, transfer to the intensive care unit (ICU) and 30-day readmission, emergency department visit, Clostridioides difficile infection, and antibiotic-associated adverse events.
RESULTS: Of 2706 moderately immunocompromised patients with pneumonia, 59% (n = 1596) received empiric BSAs. Methicillin-resistant Staphylococcus aureus and resistant gram-negative bacteria were rare (94/2706 [3.5%]). After adjustment, empiric BSA treatment was not associated with mortality, but was associated with readmission (adjusted hazard ratio [aHR], 1.32 [95% confidence interval {CI], 1.05-1.66]), transfer to ICU (aHR, 2.65 [95% CI, 1.32-5.30]), and longer hospitalization (adjusted rate ratio, 1.14 [95% CI, 1.10-1.19]).
CONCLUSIONS: Immunocompromised patients hospitalized with pneumonia often receive empiric BSAs despite low rates of MDROs. Empiric BSA use was not associated with mortality, but was associated with harm, including 30-day readmission, transfer to ICU, and longer duration of hospitalization.
METHODS: This was a target trial emulation including moderately immunocompromised (asplenia, hematologic malignancies, solid organ malignancy receiving chemotherapy, kidney transplant >1 year prior, congenital/acquired immunodeficiency, and receiving immunosuppressive medications) patients with pneumonia without risk factors for MDROs at 69 hospitals in the Michigan Hospital Medicine Safety Consortium. This study compared the receipt of empiric BSAs against antibiotics targeting typical respiratory pathogens on hospital day 1 or 2. The primary outcome was mortality. Secondary outcomes included length of stay, transfer to the intensive care unit (ICU) and 30-day readmission, emergency department visit, Clostridioides difficile infection, and antibiotic-associated adverse events.
RESULTS: Of 2706 moderately immunocompromised patients with pneumonia, 59% (n = 1596) received empiric BSAs. Methicillin-resistant Staphylococcus aureus and resistant gram-negative bacteria were rare (94/2706 [3.5%]). After adjustment, empiric BSA treatment was not associated with mortality, but was associated with readmission (adjusted hazard ratio [aHR], 1.32 [95% confidence interval {CI], 1.05-1.66]), transfer to ICU (aHR, 2.65 [95% CI, 1.32-5.30]), and longer hospitalization (adjusted rate ratio, 1.14 [95% CI, 1.10-1.19]).
CONCLUSIONS: Immunocompromised patients hospitalized with pneumonia often receive empiric BSAs despite low rates of MDROs. Empiric BSA use was not associated with mortality, but was associated with harm, including 30-day readmission, transfer to ICU, and longer duration of hospitalization.